Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
导致非病毒性肝癌发生及其对免疫检查点抑制剂反应的控制的免疫抑制机制
基本信息
- 批准号:10473837
- 负责人:
- 金额:$ 72.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-25 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adaptive Immune SystemAffectAttenuatedCancer ControlCancer EtiologyCell Adhesion MoleculesCessation of lifeClinicalClinical ResearchConduct Clinical TrialsCost SavingsCytotoxic T-LymphocytesDevelopmentDiffusionDoctor of MedicineDoctor of PhilosophyDoctor of Veterinary MedicineDrug TargetingEthanolEtiologyEuropeFibrosisGenerationsGoalsHeavy DrinkingHepatic Stellate CellHepatitis C virusHigh Fat DietHumanImmuneImmune checkpoint inhibitorImmunoglobulin AImmunologic SurveillanceImmunooncologyImmunotherapeutic agentImmunotherapyIncidenceInvestigationLiquid substanceLiverLiver FibrosisMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of liverModelingMolecularMusNivolumabObesity EpidemicOncologistOutcomePD-1 blockadePD-1/PD-L1PD-L1 blockadePDL1 inhibitorsPathogenesisPatient SelectionPatientsPharmaceutical PreparationsPharmacologyPlasma CellsPre-Clinical ModelPrevalencePrimary carcinoma of the liver cellsProceduresProtocols documentationResearch PersonnelResearch Project GrantsResistanceRoleSerumSourceSpecimenSteatohepatitisStudy modelsTherapeuticTimeTranslationsTreatment Failureadaptive immune responseantagonistcancer immunotherapychemical carcinogenchemokinechronic liver inflammationeffective therapyendoplasmic reticulum stressimprovedinnovationinterestmedical schoolsmembermortalitymouse modelnon-alcoholicnonalcoholic steatohepatitisnovelobjective response ratepre-clinical researchpredicting responsepreventproblem drinkerprogrammed cell death ligand 1programmed cell death protein 1responsestellate celltargeted treatmenttherapy outcometranslational scientisttreatment responsetumortumorigenic
项目摘要
PROJECT SUMMARY
This project will explore adaptive immune mechanisms that control development of hepatocellular carcinoma
(HCC), a leading cause of cancer-related deaths, and dictate its responsiveness to PD-1:PD-L1 checkpoint
inhibitors. Our team, including Michael Karin, Ph.D. and Shabnam Shalapour, Ph.D. at UCSD School of Medicine
and Hidekazu Tsukamoto, D.V.M., Ph.D. and Anthony El-Khoueiry, M.D. at USC Keck School of Medicine,
represents an ideal blend of basic researchers, translational scientists and oncologists who are interested in
HCC molecular pathogenesis and treatment, especially in HCC caused by non-alcoholic (NASH) and alcoholic
(ASH) steatohepatitis. Although the US incidence of HCC and its associated mortality have nearly tripled in the
past generation, insufficient effort has been made toward identification and development of innovative and
effective HCC therapies. However, the ideal and timely confluence of basic preclinical research and applied
clinical studies carried out by our team members has the potential to critically transform HCC treatment forever.
Together we found that chronic liver inflammation results in suppression of HCC-protective immunosurveillance
to support rapid malignant progression. This unique immunopathogenic mechanism renders HCC responsive to
drugs that disrupt the PD-1:PD-L1 checkpoint, but even the impressive response seen thus far and the selection
of patients who will benefit from this therapeutic approach can be further improved. Such improvements can only
be achieved by a deeper understanding of the mechanisms through which PD-1:PD-L1 inhibitors act, the factors
that determine their efficacy, and the causes of treatment failure. We will achieve these goals through integrated
studies of clinical specimens collected by Dr. El-Khoueiry and sophisticated, faithful and robust mouse models
of non-viral HCC developed by Drs. Tsukamoto, Shalapour, and Karin. The immune mechanisms that control
NASH- and ASH-driven HCC development in these models are highly similar to those that operate in human
patients. Using this integrated approach, we will pursue five specific aims: 1) determine whether serum IgA
concentrations correlate with therapeutic response to PD-1 blockade in patients with non-viral HCC; 2) develop
reliable mouse models of ASH-driven HCC; 3) compare the immunosuppressive mechanisms that contribute to
development of NASH- and ASH-driven HCC and control their response to PD-L1 blockade; 4) determine
whether excessive peritumoral fibrosis correlates with diminished response to PD-1 blockade in HCC patients;
and 5) determine whether agents that inhibit or attenuate stellate cell activation potentiate the response to PD-
1/PD-L1 blockade in non-viral HCC. The successful completion of these studies will result in substantial
improvements to HCC immunotherapy and will establish reliable procedures for identification of patients who are
most likely to benefit from PD-1/PD-L1 targeting drugs, advances that will result in significant cost savings which
may amount to hundreds of millions of dollars annually.
项目摘要
本项目将探索控制肝细胞癌发展的适应性免疫机制
(HCC)是癌症相关死亡的主要原因,并决定了其对PD-1:PD-L1检查点的反应性
抑制剂的我们的团队,包括Michael Karin博士,Shabnam Shalapour博士加州大学圣地亚哥分校医学院
和冢本秀一,D.V.M.,博士和Anthony El-Khoueiry,医学博士在南加州大学凯克医学院,
代表了基础研究人员、转化科学家和肿瘤学家的理想组合,他们对以下方面感兴趣:
HCC的分子发病机制和治疗,特别是在非酒精性(NASH)和酒精性
(ASH)脂肪性肝炎尽管美国HCC的发病率及其相关死亡率在2008年几乎增加了两倍,
在过去的几代人中,对识别和开发创新和
有效的HCC治疗。然而,基础临床前研究和应用的理想和及时的融合,
我们团队成员开展的临床研究有可能永远彻底改变HCC治疗。
我们共同发现,慢性肝脏炎症导致HCC保护性免疫监视功能受到抑制
以支持快速的恶性进展。这种独特的免疫病理机制使HCC对免疫应答反应。
破坏PD-1:PD-L1检查点的药物,但即使是迄今为止看到的令人印象深刻的反应和选择,
可以进一步提高受益于这种治疗方法的患者的比例。这种改进只能
通过更深入地了解PD-1:PD-L1抑制剂的作用机制,
决定其疗效和治疗失败的原因。我们将通过综合措施实现这些目标。
El-Khoueiry博士收集的临床标本和复杂、可靠和稳健的小鼠模型的研究
Tsukamoto、Shalapour和Karin博士开发的非病毒性HCC。免疫机制控制着
在这些模型中NASH和ASH驱动的HCC发展与在人类中运行的HCC发展高度相似。
患者使用这种综合方法,我们将追求五个具体目标:1)确定血清伊加是否
浓度与非病毒性HCC患者对PD-1阻断的治疗反应相关; 2)
可靠的ASH驱动的HCC小鼠模型; 3)比较有助于
NASH和ASH驱动的HCC的发展,并控制它们对PD-L1阻断的反应; 4)确定
过度的瘤周纤维化是否与HCC患者对PD-1阻断的反应减弱相关;
和5)确定抑制或减弱星状细胞活化的试剂是否增强对PD-1的应答。
1/PD-L1阻断非病毒性HCC。这些研究的成功完成将导致大量的
改善HCC免疫治疗,并将建立可靠的程序,用于识别
最有可能受益于PD-1/PD-L1靶向药物,这些进展将导致显著的成本节约,
每年可能高达数亿美元。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anthony Boutros El-Khoueiry其他文献
Anthony Boutros El-Khoueiry的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anthony Boutros El-Khoueiry', 18)}}的其他基金
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
导致非病毒性肝癌发生及其对免疫检查点抑制剂反应的控制的免疫抑制机制
- 批准号:
10247489 - 财政年份:2018
- 资助金额:
$ 72.53万 - 项目类别:
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
导致非病毒性肝癌发生及其对免疫检查点抑制剂反应的控制的免疫抑制机制
- 批准号:
9792372 - 财政年份:2018
- 资助金额:
$ 72.53万 - 项目类别:
NCI NCTN- Network Lead Academic Participating Site: USC
NCI NCTN-网络领导学术参与站点:USC
- 批准号:
8839740 - 财政年份:2014
- 资助金额:
$ 72.53万 - 项目类别:
NCTN - Network Lead Academic Participating Site: USC
NCTN - 网络领导学术参与站点:USC
- 批准号:
9894739 - 财政年份:2014
- 资助金额:
$ 72.53万 - 项目类别:
NCI NCTN- Network Lead Academic Participating Site: USC
NCI NCTN-网络领导学术参与站点:USC
- 批准号:
8605629 - 财政年份:2014
- 资助金额:
$ 72.53万 - 项目类别:
Clinical Protocol and Data Management: (Core 011)
临床方案和数据管理:(核心 011)
- 批准号:
8999047 - 财政年份:1996
- 资助金额:
$ 72.53万 - 项目类别:
Clinical Protocol and Data Management: (Core 011)
临床方案和数据管理:(核心 011)
- 批准号:
9359376 - 财政年份:
- 资助金额:
$ 72.53万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 72.53万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 72.53万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 72.53万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 72.53万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 72.53万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 72.53万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 72.53万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 72.53万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 72.53万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 72.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists